COMP <GO>
ROIV vs INSM // ALTMAN Z-SCORE & DEBT/EQUITY
Roivant Sciences Ltd. (NASDAQ) VS. Insmed Incorporated (NASDAQ) • 15-METRIC TALLY: ROIV 4
— INSM 5
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ROIV
LAST: $35.89 (-2.76%) • MKT CAP: $26.66B
balance-sheet
26.00
LAST: $109.31 (-2.90%) • MKT CAP: $24.70B
balance-sheet
5.25
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. INSM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | INSM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 79.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | -35.00% | +21.00 | ROIV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.80% | -3.97% | +1.17 | ROIV | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 66.70% | -131.70 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 5.25 | +20.75 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 5/9 | -2.00 | INSM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.3 | 62.2 | -8.90 | INSM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.03 | -0.03 | INSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 21.0x | +7.00 | INSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $26.66B | $24.70B | $1.96B | ROIV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | INSM REV | ROIV GROSS % | INSM GROSS % | ROIV FCF | INSM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $606.4M | — | 79.7% | -$758.6M | -$967.6M |
| FY 2024 | $29.1M | $363.7M | — | 76.4% | -$844.0M | -$705.8M |
| FY 2023 | $32.7M | $305.2M | — | — | -$766.7M | -$550.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
INSM // BETA 1.03